Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06201234 |
| Title | Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT) |
| Acronym | ELEMENT |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | German Breast Group |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | DEU |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Agaplesion Frankfurter Diakonie Kliniken gGmbH | RECRUITING | Frankfurt Am Main | Hessen | 60431 | Germany | Details |
| MVZ für Hämatologie und Onkologie Ravensburg GmbH Studienzentrum | NOT_YET_RECRUITING | Ravensburg | 88212 | Germany | Details |